Rib-X achieves fourth milestone payment in Sanofi RX-04 collaboration
The RX-04 program is focused on using a novel binding site within the ribosome to develop new classes of antibiotics to treat some of the multi-drug resistant Gram-positive
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.